Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenoty...( MONTVALE N.J. Nov. 5 /- Synvista ...),Health

MONTVALE, N.J., Nov. 5 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (Amex: SYI) announces results of a clinical trial known as the ICARE study, being presented today at the American Heart Association's (AHA) Scientific Sessions 2007 in Orlando, Florida. The study demonstrated that supplementing Vitamin E therapy in patients with Diabetes Mellitus (DM) who had the Haptoglobin 2-2 (Hp2-2) phenotype met its pre-specified, primary endpoint of decreased cardiovascular events, leading to early termination of the four-year study after just 18 months.

"We are thrilled that Dr. Andrew P. Levy and his colleagues at the Rappaport Research Institute in the Technion Faculty of Medicine, Technion- Israel Institute of Technology, Haifa, Israel, and Clalit Health Services, Haifa and Western Galilee, Israel conducted this study to evaluate the efficacy of treating Hp2-2, DM patients with Vitamin E," said Noah Berkowitz, M.D., Ph.D., President and Chief Executive Officer of Synvista. "Vitamin E has been the subject of significant controversy in recent years, with several meta-analyses showing increased mortality for patients treated with this nutraceutical. We find it validating to identify the possibility, in a large, prospective clinical trial, that patients can test their Haptoglobin type and then receive an inexpensive therapy that has demonstrated clinical benefit. This is targeted therapy at its best. Further, we believe this study provides scientific rationale for our current development platform, which is based on targeting our oxidized lipid reducing product candidate, ALT-2074, to patients with DM who test positive for Hp2-2 with our diagnostic technology for Haptoglobin."

In the placebo-controlled ICARE s
'/>"/>